BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30244409)

  • 1. Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer.
    Ishigami E; Sakakibara M; Sakakibara J; Masuda T; Fujimoto H; Hayama S; Nagashima T; Sangai T; Nakagawa A; Nakatani Y; Otsuka M
    Breast Cancer; 2019 Mar; 26(2):180-189. PubMed ID: 30244409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells.
    Zhou X; Su YX; Lao XM; Liang YJ; Liao GQ
    Oral Oncol; 2016 Feb; 53():27-35. PubMed ID: 26631955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
    Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
    Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10
    Yang C; Zhang Y; Wang R; Cheng B; Wu Y; Fu X
    Autoimmunity; 2024 Dec; 57(1):2290909. PubMed ID: 38084896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.
    Sun S; Fei X; Mao Y; Wang X; Garfield DH; Huang O; Wang J; Yuan F; Sun L; Yu Q; Jin X; Wang J; Shen K
    Cancer Immunol Immunother; 2014 Apr; 63(4):395-406. PubMed ID: 24514954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.
    Guan H; Wan Y; Lan J; Wang Q; Wang Z; Li Y; Zheng J; Zhang X; Wang Z; Shen Y; Xie F
    Sci Rep; 2016 Oct; 6():35651. PubMed ID: 27762298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
    Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
    Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.
    Quan S; Sheng JR; Abraham PM; Soliven B
    Clin Exp Immunol; 2016 Apr; 184(1):50-61. PubMed ID: 26671281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of FOXP3 expression in triple-negative breast cancer.
    Lee S; Cho EY; Park YH; Ahn JS; Im YH
    Acta Oncol; 2013 Jan; 52(1):73-81. PubMed ID: 23075422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection.
    Liu Y; Cheng LS; Wu SD; Wang SQ; Li L; She WM; Li J; Wang JY; Jiang W
    Clin Sci (Lond); 2016 Jun; 130(11):907-19. PubMed ID: 26980345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
    Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
    BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer.
    Wang WW; Yuan XL; Chen H; Xie GH; Ma YH; Zheng YX; Zhou YL; Shen LS
    Oncotarget; 2015 Oct; 6(32):33486-99. PubMed ID: 26378021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of regulatory B cells (Bregs) in the Tregs-amplifying effect of Sirolimus.
    Song J; Xiao L; Du G; Gao Y; Chen W; Yang S; Fan W; Shi B
    Int Immunopharmacol; 2016 Sep; 38():90-6. PubMed ID: 27258186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
    Shou J; Zhang Z; Lai Y; Chen Z; Huang J
    BMC Cancer; 2016 Aug; 16(1):687. PubMed ID: 27566250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
    deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
    Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.